William Blair Issues Positive Estimate for ZVRA Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Investment analysts at William Blair upped their Q1 2025 EPS estimates for shares of Zevra Therapeutics in a note issued to investors on Wednesday, March 12th. William Blair analyst S. Corwin now expects that the company will post earnings of ($0.24) per share for the quarter, up from their previous estimate of ($0.30). The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.95) per share. William Blair also issued estimates for Zevra Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.11) EPS, FY2025 earnings at ($0.65) EPS and FY2026 earnings at $0.12 EPS.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.28). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The firm had revenue of $12.00 million for the quarter, compared to analysts’ expectations of $8.93 million.

Other equities analysts have also recently issued reports about the stock. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zevra Therapeutics in a report on Thursday. Canaccord Genuity Group boosted their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a report on Thursday. Guggenheim boosted their price target on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a report on Thursday. Cantor Fitzgerald restated an “overweight” rating and set a $25.00 price target on shares of Zevra Therapeutics in a report on Wednesday. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a report on Wednesday. Eight equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $22.14.

Zevra Therapeutics Trading Up 4.7 %

NASDAQ ZVRA opened at $8.31 on Friday. Zevra Therapeutics has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock has a market cap of $443.55 million, a price-to-earnings ratio of -4.22 and a beta of 1.98. The firm’s 50 day moving average price is $7.93 and its two-hundred day moving average price is $8.15.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Woodline Partners LP lifted its position in Zevra Therapeutics by 2.2% during the 4th quarter. Woodline Partners LP now owns 4,139,593 shares of the company’s stock worth $34,524,000 after acquiring an additional 90,940 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its position in Zevra Therapeutics by 462.4% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,650,000 shares of the company’s stock worth $30,441,000 after acquiring an additional 3,001,000 shares during the last quarter. Vanguard Group Inc. lifted its position in Zevra Therapeutics by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 2,824,212 shares of the company’s stock worth $23,554,000 after acquiring an additional 68,151 shares during the last quarter. FMR LLC lifted its position in Zevra Therapeutics by 282,687.5% during the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after acquiring an additional 2,312,384 shares during the last quarter. Finally, Altium Capital Management LLC lifted its position in Zevra Therapeutics by 8.8% during the 4th quarter. Altium Capital Management LLC now owns 1,850,000 shares of the company’s stock worth $15,429,000 after acquiring an additional 150,000 shares during the last quarter. Institutional investors and hedge funds own 35.03% of the company’s stock.

Insider Activity at Zevra Therapeutics

In related news, CEO Neil F. Mcfarlane sold 61,273 shares of Zevra Therapeutics stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total value of $481,605.78. Following the completion of the sale, the chief executive officer now owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. The trade was a 21.63 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Joshua Schafer sold 10,500 shares of the business’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the transaction, the executive vice president now directly owns 29,486 shares of the company’s stock, valued at approximately $231,759.96. This represents a 26.26 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 85,773 shares of company stock valued at $674,176. Insiders own 2.40% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.